相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
Christian Sordo-Bahamonde et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)
Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC).
Ying Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases
Karolina Wojciechowicz et al.
CELLULAR IMMUNOLOGY (2022)
Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.
Jun Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.
Russell J. Schilder et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N. Amaria et al.
NATURE (2022)
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
Claire Battin et al.
FRONTIERS IN IMMUNOLOGY (2022)
Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction
Alicia Landeira-Vinuela et al.
FRONTIERS IN IMMUNOLOGY (2022)
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
Ilana Mandel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
Daniele Fanale et al.
FRONTIERS IN ONCOLOGY (2022)
Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas
Jun Ma et al.
BLOOD (2022)
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study
Qinchuan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes
Amany M. Kamal et al.
CLINICAL BIOCHEMISTRY (2021)
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies
Joao Gorgulho et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
Christian Sordo-Bahamonde et al.
CANCERS (2021)
Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma
Shaowen Li et al.
Aging-US (2021)
Cancer immunotherapy: it's time to better predict patients' response
Charlotte Pilard et al.
BRITISH JOURNAL OF CANCER (2021)
Up-regulation of BTLA expression in myeloid dendritic cells associated with the treatment outcome of neonatal sepsis
Wan-dang Wang et al.
MOLECULAR IMMUNOLOGY (2021)
BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes
Xiangmin Li et al.
ONCOTARGETS AND THERAPY (2020)
Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma
Minh Phuong Dong et al.
SCIENTIFIC REPORTS (2020)
T follicular helper cells in germinal center B cell selection and lymphomagenesis
Michelle A. Mintz et al.
IMMUNOLOGICAL REVIEWS (2020)
The synergism of B and T lymphocyte attenuator (BTLA) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) attenuated acute T-cell mediated rejection and prolonged renal graft survival
Hengcheng Zhang et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2020)
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Robert Ballotti et al.
MOLECULAR CANCER (2020)
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
Benjamin Bian et al.
ONCOIMMUNOLOGY (2019)
The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis
Michelle A. Mintz et al.
IMMUNITY (2019)
BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease
Christoph Oster et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma
Nausicaa Malissen et al.
ONCOIMMUNOLOGY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival
Jiayi Zhang et al.
SCIENTIFIC REPORTS (2019)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
Qinchuan Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Yu-Li Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Expression and clinical significance of B and T lymphocyte attenuator on CD4+ and CD8+ T cells from patients with pulmonary tuberculosis
Xinghua Shen et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2019)
High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation
Joaquim Carreras et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2019)
Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness
Sean F. Monaghan et al.
MOLECULAR MEDICINE (2018)
Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection
Zijie Wang et al.
MEDICAL SCIENCE MONITOR (2018)
The immune checkpoint, HVEM may contribute to immune escape in non small cell lung cancer lacking PD-L1 expression
Shengxiang Ren et al.
LUNG CANCER (2018)
Immune checkpoint blockade in infectious diseases
Michelle N. Wykes et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
Cynthia L. Gay et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality
Anna Lange et al.
PLOS ONE (2017)
Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
Xiuwen Lan et al.
ONCOTARGETS AND THERAPY (2017)
Cancer therapies in HIV cure research
Thomas A. Rasmussen et al.
CURRENT OPINION IN HIV AND AIDS (2017)
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
Carmen Stecher et al.
FRONTIERS IN IMMUNOLOGY (2017)
Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer
Julia Y. S. Tsang et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade
Katharina Grabmeier-Pfistershammer et al.
CLINICAL IMMUNOLOGY (2017)
Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Krit Ritthipichai et al.
CLINICAL CANCER RESEARCH (2017)
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Michael Boice et al.
CELL (2016)
Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells
Andrew Jones et al.
IMMUNITY (2016)
The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Lindsay K. Ward-Kavanagh et al.
IMMUNITY (2016)
Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis
Eduardo Huarte et al.
JOURNAL OF IMMUNOLOGY (2016)
The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
Bin Yang et al.
PLOS ONE (2016)
BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma
Qiyi Zhao et al.
ONCOIMMUNOLOGY (2016)
Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM
Yuwen Zhu et al.
SCIENCE ADVANCES (2016)
Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer
Seiji Oguro et al.
CANCER SCIENCE (2015)
BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties
Cara L. Haymaker et al.
ONCOIMMUNOLOGY (2015)
Significant Involvement of Herpesvirus Entry Mediator in Human Esophageal Squamous Cell Carcinoma
Kazuhiro Migita et al.
CANCER (2014)
Herpesvirus entry mediator (HVEM) attenuates signals mediated by the lymphotoxin β receptor (LTβR) in human cells stimulated by the shared ligand LIGHT
John Bechill et al.
MOLECULAR IMMUNOLOGY (2014)
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma
Jessica Okosun et al.
NATURE GENETICS (2014)
An Agonistic Anti-BTLA mAb ( 3C10) Induced Generation of IL-10-Dependent Regulatory CD4+T Cells and Prolongation of Murine Cardiac Allograft
Masateru Uchiyama et al.
TRANSPLANTATION (2014)
A Lymphotoxin-β-Specific Receptor
Paul D. Crowe et al.
JOURNAL OF IMMUNOLOGY (2014)
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Christine Pasero et al.
IMMUNOLOGY LETTERS (2013)
B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function
Gang Cai et al.
JOURNAL OF GASTROENTEROLOGY (2013)
CD160 Activation by Herpesvirus Entry Mediator Augments Inflammatory Cytokine Production and Cytolytic Function by NK Cells
John R. Sedy et al.
JOURNAL OF IMMUNOLOGY (2013)
CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA
Rachel Flynn et al.
PLOS ONE (2013)
BTLA Interaction with HVEM Expressed on CD8+ T Cells Promotes Survival and Memory Generation in Response to a Bacterial Infection
Marcos W. Steinberg et al.
PLOS ONE (2013)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
Julien Fourcade et al.
CANCER RESEARCH (2012)
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy
Christine Pasero et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation
Willemijn Hobo et al.
JOURNAL OF IMMUNOLOGY (2012)
BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction
Nicholas J. Shubin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway
Yukimi Sakoda et al.
BLOOD (2011)
TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14)
Carl F. Ware et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation
Marcos W. Steinberg et al.
IMMUNOLOGICAL REVIEWS (2011)
Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations
Pejman Soroosh et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Jr-Wen Shui et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM
Theresa L. Murphy et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis
K-John J. Cheung et al.
CANCER RESEARCH (2010)
BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
Laurent Derre et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression
Joern C. Albring et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function
Nacer-Eddine Serriari et al.
JOURNAL OF IMMUNOLOGY (2010)
HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation
M. L. del Rio et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
High Expression of the Inhibitory Receptor BTLA in T-Follicular Helper Cells and in B-Cell Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Hasni M'Hidi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Association study between B- and T-lymphocyte attenuator gene and type 1 diabetes mellitus or systemic lupus erythematosus in the Japanese population
M. Inuo et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2009)
Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation
Jerome Giustiniani et al.
JOURNAL OF IMMUNOLOGY (2009)
B and T Lymphocyte Attenuator Regulates B Cell Receptor Signaling by Targeting Syk and BLNK
Andrew C. Vendel et al.
JOURNAL OF IMMUNOLOGY (2009)
T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment
Timothy C. Cheung et al.
JOURNAL OF IMMUNOLOGY (2009)
Unconventional ligand activation of herpesvirus entry mediator signals cell survival
Timothy C. Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator
Yoshihiro Oya et al.
ARTHRITIS AND RHEUMATISM (2008)
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways
Carl F. Ware
IMMUNOLOGICAL REVIEWS (2008)
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
Guifang Cai et al.
NATURE IMMUNOLOGY (2008)
Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation
Michelle A. Hurchla et al.
JOURNAL OF IMMUNOLOGY (2007)
Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin:: A possible role for CD160 in skin inflammation
Sofia Abecassis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation
Carsten Krieg et al.
NATURE IMMUNOLOGY (2007)
A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity
Jerome Giustiniani et al.
JOURNAL OF IMMUNOLOGY (2007)
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA
Maya Gavrieli et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Functional analysis of B and T lymphocyte attenuator engagement on CD4+ and CD8+ T cells
C Krieg et al.
JOURNAL OF IMMUNOLOGY (2005)
Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation
M Maeda et al.
JOURNAL OF IMMUNOLOGY (2005)
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells
MA Hurchla et al.
JOURNAL OF IMMUNOLOGY (2005)
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator
LC Gonzalez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator
JR Sedy et al.
NATURE IMMUNOLOGY (2005)
Cutting edge: Engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset
A Barakonyi et al.
JOURNAL OF IMMUNOLOGY (2004)
Minor histocompatibility antigens: Allo target molecules for tumor-specific immunotherapy
E Goulmy
CANCER JOURNAL (2004)
An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection
P Han et al.
JOURNAL OF IMMUNOLOGY (2004)
Molecules and mechanisms of the graft-versus-leukaemia effect
M Bleakley et al.
NATURE REVIEWS CANCER (2004)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N Watanabe et al.
NATURE IMMUNOLOGY (2003)
LIGHT-HVEM signaling and the regulation of T cell-mediated immunity
SW Granger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity
P Le Bouteiller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression
M Nikolova et al.
INTERNATIONAL IMMUNOLOGY (2002)
The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity
Y Morel et al.
JOURNAL OF IMMUNOLOGY (2001)
Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor
Y Morel et al.
JOURNAL OF IMMUNOLOGY (2000)
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response
K Tamada et al.
JOURNAL OF IMMUNOLOGY (2000)
The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells
IA Rooney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
